Sanofi and Regeneron said today they will appeal a federal judge's ban on U.S. sales of Praluent in a patent case with Amgen.

Allergan today offered up a preview for 2017, projecting mid-single-digit percentage growth for net revenue and double-digit growth in earnings per share.

​​​​​​​How long does it take to lose $96 billion in market value? If you’re the three worst-performing major pharmas, only one year.

At Eli Lilly, the new year comes with a shakeup in its commercial organization, with vet Enrique Conterno taking the reins in the U.S. and ex-Novartis exec…

Greek prosecutors have raided Novartis offices and questioned 178 people in a bribery investigation launched after corruption allegations surfaced in local…

Endo is shaking the personnel tree again, this time in marketing. Recent hire Joseph Ciaffoni is moving out as former Sanofi exec Patrick Barry takes over.

Biogen's $375,000-plus price on its new drug Spinraza set analysts and market watchers atwitter. Will the ultra-orphan med become the "Sovaldi of…

We won’t surprise anyone by saying that Topic No. 1 in pharma this year was drug pricing. We’ll give you one guess as to whether 2017 will be more of the same…

Actelion investors are said to be getting very restless over the fact that the biotech has yet to bring a deal with Sanofi home for the holidays but shares…

Corporate